nms

Eventi e congressi

NMS parteciperà e/o porterà risultati ai seguenti eventi.
I poster saranno disponibili su richiesta al seguente indirizzo: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.

2017

  • 24-27 giugno
    EACR AACR SIC:The challenges of optimising immuno and targeted therapies - from cancer biology to clinic
    Firenze, Italia
    Web link
    Abstract 318
    NMS-P088 is a small molecule potent CSF1R kinase inhibitor with macrophages immunomodulatory activity
  • 12-13 giugno
    18th Annual Drug Discovery Summit
    Berlino , Germany
    Web link
  • 8-9 giugno
    VII Congresso nazionale organizzato da ISMRM Italian Chapter
    Gaeta, Italia
    Web link
  • 1-5 aprile
    AACR 2017
    Washington, USA
    Web link
    Abstract 5163
    Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma
    Abstract 2082
    NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models
  • 5-7 marzo
    Fragments 2017 - 6th RSC-BMCS Fragment-based Drug Discovery meeting
    Vienna, Austria
    Web link
    Abstract: P04
    Purinome targeted, fragment based lead discovery: identification of novel HSP90 inhibitors
  • 26-27 gennaio
    ER Stress, Autophagy & Immune System
    Bruges, Belgium
    Web link

Archivio 2016

  • Novembre 29 - Dicembre 2
    28th EORTC-NCI-AACR Symposium "Molecular targets and cancer therapeutics
    Monaco, Germany
    Web link
    Abstract 388
    NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapies
  • Ottobre 13-15
    Cancer bio-immunotherapy - XIV NIBIT Meeting
    Siena, Italy
    Web link
  • Ottobre 10-13
    7th Annual ADC Summit meeting
    San Diego, CA
    Web link
    Abstract 24
    NMS-P945: a novel highly active thienoindole payload for antibody drug conjugation generation
  • Settembre 11
    XXIV National Meeting on Medicinal Chemistry
    Perugia, Italy
    Web link
  • Agosto 28 - Settembre 1
    XXIV EFMC International Symposium on Medicinal Chemistry
    Berlin, Germany
    Web link
  • Luglio 15-16
    Fifth International Chordoma Research Workshop
    Boston, USA
    Web link
  • Giugno 15-17
    13th Annual Meeting of the Bioinformatics Italian Society
    Fischiano, Italy
    Web link
  • Giugno 13-14
    17th Annual Drug Discovery Summit 2016
    Berlin, Germany
    Web link
  • Maggio 25
    9th MS-PHARMADAY
    S. Palomba, Italy
    Web link Oral presentation Liquid Chromatography - Mass Spectrometry: Where we are now and where we are going (A perfect troubled marriage II)
  • Maggio 12
    Medicina di precisione e target in oncologia
    Milan, Italy
    Web link
  • Aprile 16-20
    AACR Annual Meeting
    Ernest N. Morial Convention Center
    New Orleans, Louisiana, USA.

    Web link
    Abstract 1223
    NMS-P293, a novel potent and selective PARP-1 inhibitor with high anti-tumor efficacy and tolerability

    Abstract 3795
    Novel and selective MELK kinase inhibitors active in breast cancer cell lines
    Abstract 2136
    Entrectinib is effective against the gatekeeper and other emerging resistance mutations in NTRK-, ROS1- and ALK- rearranged cancers
    Abstract 2690
    A Novel Antibody-Drug Conjugate Directed to the ALK Receptor Tyrosine Kinase Demonstrates Efficacy in Models of Neuroblastoma
  • Marzo 9-12
    Hematological malignancies from mechanism to therapy symposium
    Milan
    Web link
    Abstract B4
    NMS-P088, a novel dual FLT3-KIT inhibitor with an excellent preclinical therapeutic window suitable for therapy of AML, including cases harboring gatekeeper mutations variants
  • Gennaio 22
    Innovative therapy, monoclonal antibodies and beyond, 6th edition
    Milan, Italy
    Web link

Archivio 2015

  • Novembre 5-9
    AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    Boston, MA, USA
    Web link
    Abstract A149
    NMS-P945, a highly active payload for antibody drug conjugates generation

    Abstract A179
    NMS-P113, a novel orally available JAK2 selective inhibitor
  • Giugno 20-23
    Anticancer drug action and drug resistance: from cancer biology to the clinic, Florence
    Florence
    Web link
  • Aprile 18-22
    AACR 2015
    Philadelphia
    Web link
    Abstract 798
    NMS-P088, a dual FLT3-KIT inhibitor active also on gatekeeper mutations and devoid of QTc prolongation

    Abstract 1638
    Preclinical characterization of the novel TTK kinase inhibitor S81694 for the treatment of triple negative breast cancer
    Abstract 74
    Establishment and characterization of the new sacral chordoma cell line Chor-IN-1
    Abstract 2851
    Preclinical characterization of NMS-P648, a novel and potent PARP-1/-3 inhibitor
  • Marzo 2-4
    TAT congress
    Paris
    Web link
  • Febbraio 23-25
    World ADC congress
    Frankfurt
    Web link

Archivio 2014

Archivio 2013

  • Ottobre 11-13
    XV Congresso Nazionale AIOM
    Milan, Italy
    Web link
    Abstract
    Identification of a TPM3-TRKA rearrangement in human colon carcinoma, and development of a methodology to identify patients for treatment with TRK inhibitors
    Bosotti R, Veronese S, Somaschini A, Cammarota R, Ardini E, Raddrizzani L, Milani A, Alzani R, Pesenti E, Sartore Bianchi A, Gambacorta M, Pierotti M, Galvani A, Siena S, Isacchi A
  • Settembre 10-13
    XXII National Meeting on Medicinal Chemistry
    Rome, Italy
    Web link
    Oral presentation
    Applications of Noncovalent ESI-MS in Drug Discovery
    Riccardi Sirtori F
  • Giugno 20-22
    25th Pezcoller Symposium: "Metabolism and Tumorigenesis"
    Trento, Italy
    Web link
  • Aprile 6-10
    AACR 2013
    Washington, USA
    Web link
    Abstract 2091
    Identification of a highly potent, selective and orally available RET inhibitor with antitumor efficacy in RET-dependent tumor models
    Ardini E, Banfi P, Quartieri F, Polucci P, Avanzi N, Ballinari D, Mancini L, Felder E, Donati D, Galvani A, Pesenti E, Isacchi A, Menichincheri M

    Abstract 2092
    The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models
    Ardini E, Menichincheri M, Banfi P, Casero D, Giorgini ML, MB Saccardo, Amboldi N, Avanzi N, Donati D, Isacchi A, Pesenti E, Galvani A

    Abstract 2097
    Targeting aneuploidy with NMS-P153, a tight binder inhibitor of the spindle assembly checkpoint MPS1 (TTK) kinase
    Colombo R, Caldarelli M, Giorgini ML, De Grassi A, Ciomei M, Pezzetta D, Ballinari D, Montagnoli A, Pesenti E, Donati D, Galvani A

    Abstract 3259
    Novel isoquinolinone derivatives with dual PARP-1/PARP-3 inhibitory activity are highly active against pTEN mutated colorectal cancer and glioblastoma models
    Montagnoli A, Rainoldi S, Mazzoleni S, Ciavolella A, Lupi R, Casale E, Ciomei M, Pesenti E, Donati D, Galvani A, Papeo G

Archivio 2012

  • Novembre 6-9
    24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    Dublino, Ireland
    Web link
    Abstract 231
    A novel siRNA screening approach for target identification in oncology: focus on purinome enzymes
    F. Gasparri, LM. Gianellini, ML. Giorgini, A. Carugo, L. Raddrizzani, C. Perrera, R. Lupi, A. Isacchi, A. Galvani, R. Colombo

    Abstract 309
    Characterization of a novel, highly potent and selective RET inhibitor with antitumor efficacy in RET dependent models
    E. Ardini, N. Amboldi, N. Avanzi, P. Banfi, C. Cristiani, D. Donati, A. Galvani, A. Isacchi, E. Pesenti, M. Menichincheri

    Abstract 517
    NMS-P153, a tight-binder inhibitor of the spindle assembly checkpoint kinase MPS1
    R. Colombo, M. Caldarelli, ML, Giorgini, O. Milani, N. Avanzi, F. Sola, E. Pesenti, D. Donati, A. Galvani

    Abstract 544
    Characterization of potent and well tolerated second generation FLT3 Inhibitors
    M. Ciomei, N. Amboldi, S. Cribioli, D. Donati, I. Fraietta, A. Galvani, C. Nuccio, E. Pesenti, G. Texido Romero, A. Lombardi Borgia
  • Ottobre 27-29
    XIV Congresso Nazionale di Oncologia Medica
    Roma, Italy
    Web link
  • Settembre 2-6
    EFMC-ISMC 2012, 22nd International Symposium on Medicinal Chemistry
    Berlin, Germany
    Web link
  • Luglio 17-20
    XXII National Meeting on Medicinal Chemistry
    Palermo, Italy
    Web link
    Oral presentation
    The discovery, synthesis and SAR studies of a new class of potent and selective PARP-1 inhibitors as anticancer agents
    GL. Papeo
  • Giugno 27-29
    XI National Biotechnology Congress
    Varese, Italy
    Web link
    Oral presentation
    An integrated approach for the development of anticancer drugs
    A. Isacchi
  • Giugno 14-16
    Molecular basis for resistance to target agents
    Trento, Italy
    Web link
  • Giugno 10-12
    12th Annual drug discovery leaders summit
    Zurigo, Switzerland
    Web link
  • Maggio 30-31
    Drug Discovery Automation
    Hamburg, Germany
    Web link
  • Maggio 2-4
    Ninth Annual Meeting of the Bioinformatics Italian Society
    Catania, Italy
    Web link
    Abstract
    A comprehensive dataset including 16 loci based DNA fingerprinting of a broad tumour cell line panel for cancer research
    A. Somaschini, E. Scacheri, A. Nuzzo, N. Amboldi, D. Ballinari, G. Ukmar, A. Isacchi, R. Bosotti

    Abstract
    An interactive tool enabling a comparative analysis of STR profiles
    G.Ukmar, R. Bosotti, A. Somaschini, J. Malysko, L. Raddrizzani, G. Masetti, A. Milani, E. Scacheri, A. Isacchi, A. Nuzzo
  • Aprile 19-20
    Terzo congresso annuale organizzato dall'Italian Chapter dell'ISMRM, Napoli
    Napoli, Italy
    Web link
    Oral presentation
    MRI evaluation of dendritic cell vaccination protocol in a murine model of breast cancer (MMTV-hRas)
    M. Russo, A. Degrassi
  • Aprile 15-17
    6° Meeting di Nuove Prospettive in Chimica Farmaceutica
    Riccione, Italy
    Web link
    Oral presentation
    NMS-P715: different sinthetic approaches toward the synthesis of a potent and selective MPS1 Kinase inhibitor
    H. Posteri
  • Marzo 31-Aprile 4
    AACR 2012
    Chicago, IL
    Web link
    Oral presentation Abstract 2940
    Identification of potent VCP/p97/CDC48 inhibitors with distinct biochemical mechanisms including a reversible, allosteric inhibitor that activates the unfolded protein response, induce autophagy and cancer cell death
    P. Magnaghi, R. D'Alessio, B. Valsasina, N.R. Avanzi, S. Rizzi, D. Asa, F.Gasparri, L. Cozzi, U. Cucchi, C. Orrenius, P. Polucci, D. Ballinari, C. Perrera, A. Leone, G.Cervi, A. Galvani, D. Donati, T.O'Brien, P.K. Jackson, A. Isacchi

    Abstract 1775
    Characterization of New Highly Selective and Potent PARP-1 Inhibitors
    A.Montagnoli, G.Papeo, S. Rainoldi, A. Ciavolella, F. Sola, R. Lupi, M. Ciomei, A. Cirla, A. Scolaro, H. Posteri, D. Donati, E. Felder, A. Isacchi, E. Pesenti, A. Galvani

    Abstract 3754
    Characterization of NMS-P285, a new highly selective and potent BRAF inhibitor
    M. Pulici, N. Amboldi, W. Pastori, C. Marzoionni, G. Traquandi, S. Cribioli, R. Lupi, M. Modugno, E. Casale, A. Scolaro, E. Felder, D. Donati, A. Isacchi, E. Pesenti, A.Galvani, M. Ciomei
  • Febbraio 4-8
    SLAS 2012
    San Diego, CA
    Web link
  • Febbraio 1-2
    World Cancer Metabolism Summit
    Washington, D.C.
    Web link

Archivio 2011

  • Novembre 21-23
    Computationally Driven Drug Discovery Meeting
    L'Aquila, Italy
    Web link
  • Novembre 11-16
    EORTC Meeting 2011: Molecular Targets and Cancer Therapeutics
    San Francisco, CA
    Web link
    Abstract
    In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori
    E. Ardini, M. Menichincheri, P. Banfi, MB. Saccardo, L. Rusconi, N. Avanzi, N. Amboldi, D. Casero, F. Zuccotto, J. Bertrand, M. Fasolini, A. Isacchi, D. Donati, E. Pesenti, A. Galvani

    Abstract
    NMS-P948, a potent dual FLT3/KIT inhibitor, also active on secondary resistance mutations
    C. Ciomei, I. Fraietta, A. Marsiglio, D. Casero, M. Nesi, D. Donati, A. Isacchi, E. Pesenti, A. Galvani, A. Lombardi Borgia

    Abstract
    Targeting the Mitotic Checkpoint with NMS-P153 a Novel MPS1 Kinase Inhibitor
    R. Colombo, M. Caldarelli, ML. Giorgini, F. Sola, P. Cappella, C. Perrera, N. Avanzi, JA. Bertrand, E. Pesenti, A. Isacchi, D. Donati, A. Galvani

    Abstract
    Antitumor activity of GBR 500, a monoclonal VLA-2 antibody
    S. Hou, E. Pesenti, L. Mancini, H. Mottl
  • Novembre 6-9
    7th NCRI Cancer Conference
    Liverpool,UK
    Web link
  • Novembre 5-7
    XIII Congresso Nazionale di Oncologia Medica
    Bologna, IT
    Web link
  • Ottobre 25-28
    3rd World ADC Summit
    San Francisco, CA
    Web link
  • Ottobre 15-18
    Translation of the Cancer Genome: Scientific, Clinical, and Operational Challenges
    San Francisco, CA
    Web link
  • Ottobre 5-8
    29° Congresso Nazionale di Citometria
    Salerno, IT
    Web link
    Abstract
    IRIS™Dots nanoparticles as a novel tool for flow cytometry analysis and multi cellular culture approach
    P. Cappella, A. Giannitti, C. Bertolino, G. Caputo, J. Moll,A.Galvani
  • Settembre 23-27
    The European Multidisciplinary Cancer Congress
    Stockholm, SW
    Web link
  • Settembre 21-22
    Biacore and MicroCal User's meeting
    Assago, IT
    Web link
    Oral presentation
    Isothermal Calometric contributions to drug discovery at Nerviano Medical Sciences
    M. Fasolini
  • Settembre 11-16
    XXIV Congresso Nazionale della Società Chimica Italiana
    Lecce, IT
    Web link
    Oral presentation
    Synthesis and SAR of New Pyrazolo[4,3-h]quinazoline-3-carboxamide Derivatives as Potent and Selective MPS1 Kinase Inhibitors
    M. Caldarelli
  • Agosto 21-25
    ASMC Advances in Synthetic and Medicinal Chemistry
    St. Petersburg, Russia
    Web link
  • Luglio 6-8
    3rd WIN Symposium in personalized cancer medicine
    Paris, FR
    Web link
    Oral presentation
    A successful interaction between Academia, Pharma (Nerviano Medical Sciences) and Oncology network ofLombardy
    A. Isacchi, A. Galvani
  • Giugno 30
    Joint Meeting on medicinal chemistry
    Catania, Italy
    Web link
    Oral presentation
    Cdc7 kinase inhibitors: a new approach for anticancer therapy
    M. Menichincheri
  • Giugno 20-23
    Cancec Proteomics - Systems Biology, Developmental Models & Data Integration
    Dublin, IR
    Web link
  • Giugno, 8-9
    12th Annual Drug Discovery Leaders Summit
    Zurigo, Switzerland
    Web link
  • Giugno 6-8
    Next-Gen Kinase Inhibitors
    Cambridge (MA)
    Web link
  • Giugno 7-8
    6th Annual Cell-Based Assays Meeting
    Berlin, Germany
    Web link
    Oral presentation
    Increasing the throughput: Scaling high-content screening to high-throughput screening for lead discovery and optimisation
    F. Gasparri
  • Giugno 6-8
    Next-Gen Kinase Inhibitors
    Cambridge, MA
    Web link
  • Maggio 17
    Tackling attrition in drug discovery & development
    Verona, IT
    Web link
  • Maggio 10
    2° Luciferase Symposium "What is GLOing on in your cells?"
    Milan, Italy
    Web link
    Oral presentation
    Kinase Glo® and ADP GloTM: Universal Bioluminescent Systems to Monitor Protein Kinases Activities
    A. Leone
  • Aprile 13-15
    GPCR & Kinase target conference
    London, UK
    Web link
    Oral presentation
    Cdc7 kinase: a new target for drug development
    A. Montagnoli
  • Aprile 2-6
    AACR
    Orlando, US
    Web link
    Abstract LB-294
    GBR 500, a monoclonal VLA-2 antibody inhibits tumor and metastasis growth but not extravasation in a prostate cancer animal model
    A. Attinger, S. Hou, E.A. Pesenti, L. Mancini, H. Mottl
  • Marzo 31- Aprile 1
    Risonanza Magnetica in Medicina: dalla ricerca tecnologica avanzata alla pratica clinica
    Roma, Italy
    Web link
    Abstract
    Multimodal imaging in an orthotopic mouse model of pancreatic cancer
    Russo M, Mancini L, Texido G, Veronelli W, Pesenti E, Degrassi A
    Abstract
    In vivo imaging of labelled neural stem cells in a mouse model of spinal cord injury
    Degrassi A, Russo M, Ottobrini L, Lui R, Merli D, Marfia G, Gorio A, Pesenti E, Lucignani G
  • Marzo 22-23
    10th Annual Targets & Tools: Protein Kinases
    Berlin, Germany
    Web link
    Oral presentation
    Selectivity of kinase inhibitors in the context of the emergence of drug resistance
    J. Moll
  • Marzo 7-9
    TAT 2011
    Paris, FR
    Web link
  • Marzo 7-8
    Global Discovery & Development Innovation Forum Summit 2011
    London, UK
    Web link
    Oral presentation
    Overcoming drug resistance in oncology therapeutics
    J. Moll
  • Febbraio 23-24
    6th Annual Biomarkers Congress 2011
    Manchester, UK
    Web link
  • Febbraio 5-8
    Cell Cycle Regulators: Inhibitors and Cancer
    Vienna, Austria
    Web link
    Oral presentation
    Destabilizing aneuploidy by targeting cell cycle and mitotic checkpoint proteins in cancer cells: focus on MPS1 inhibitorsDestabilizing aneuploidy by targeting cell cycle and mitotic checkpoint proteins in cancer cells: focus on MPS1 inhibitors
    R. Colombo

Archivio 2010

  • Novembre 16-19
    EORTC-NCI-AACR
    Berlin, Germany
    Web link
    Abstract
    Pharmacological characterization of NMS-P506, a novel second generation HSP90 inhibitor
    S. Mantegani, N. Amboldi, A. De Ponti, L. Gianellini, M. Guanci, M. Paolucci, D. Donati, E. Pesenti, A. Isacchi

    Abstract
    NMS-P118, a Parp-1 selective inhibitor with efficacy in DNA repair deficient tumor models
    A. Montagnoli, S. Rainoldi, F. Sola, H. Posteri, R. Lupi, E. Pesenti, D. Donati, J. Moll, D. Pezzetta, G. Papeo

    Abstract
    Activity of the Cdc7 inhibitor NMS-1116354 as single agent and in combination in breast cancer models
    A. Montagnoli, D. Ballinari, A. Ciavolella, S. Rainoldi, M. Menichincheri, E. Pesenti, A. Galvani, A. Isacchi, J. Moll

    Abstract
    Identification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancer
    E. Ardini, A. Lombardi Borgia, C. De Ponti, N. Amboldi, D. Ballinari, M.B. Saccardo, P. Magnaghi, E. Pesenti, A. Isacchi, A. Galvani

    Abstract
    NMS-E628, a potent and orally available small molecule inhibitor of Anaplastic Lymphoma Kinase, reduces tumor growth in an intracranial model of ALK-dependent NSCLC
    E. Ardini, M. Menichincheri, P. Magnaghi, C. De Ponti, N. Amboldi, A. Degrassi, M. Russo, P. Orsini, E. Pesenti, A. Galvani
  • Ottobre 6-8
    MASSA
    Milano, IT
    Web link
    Oral presentation
    Setup of a Flow Injection Method for the Study of Non-Covalent Interaction on Biopolymers
    F. Riccardi Sirtori
  • Settembre 29-Ottobre 2
    XXVIII Conferenza Nazionale di Citometria
    Urbino, IT
    Web link
    Oral presentation
    Click chemistry" e analoghi della BrdU: nuove strategie nello studio della sintesi del DNA
    P. Cappella
  • Settembre 29-30
    Optimizing Early Phase Oncology Studies to Accelerate Proof of Concept
    Brussels, Belgium
    Web link
    Oral presentation
    Case Studies from Nerviano Medical Sciences: Planning and Implementing FIH Studies
    S. Crippa
  • 27-28 Settembre 2010
    NIH CTEP Meeting
    Bethesda, USA
    Web link
    Oral Presentation
    Preclinical characterization of ALK inhibitor NMS-E628 in ALCL and NSCLC tumor models
    A. Galvani
  • Settembre 21-22
    Innovation in Phase I clinical development
    Munich, Germany
    Web link
    Oral presentation
    Resistance mechanisms of targeted therapies
    J. Moll
  • Settembre 21-22
    ESSCA 2010
    Valencia, Spain
    Web link
    Oral presentation
    BrdU versus "Click chemistry" : new opportunitis for DNA synthesis in flow and image cytometry
    P. Cappella
  • Settembre 12-16
    NMMC 2010 - XX National Meeting on Medicinal Chemistry
    Abano Terme, IT
    Web link
    Oral presentation
    Development of pyrazolo-quinazolines as CDK inhibitors: identification of PHA-848125, a potent, orally available compound
    MG. Brasca

    Abstract
    Identification of N-{6,6-DIMETHYL-5-[(1-METHYLPIPERIDIN-4-YL)CARBONYL]-1,4,5,6-TETRAHYDRO PYRROLO[3,4-c]PYRAZOL-3-YL}-3-METHYLBUTANAMIDE, a potent CDK inhibitor suitable for intravenous dosing
    P.Orsini
  • Settembre 5-9
    XXIst International Symposium on Medicinal Chemistry
    Brussels, Belgium
    Web link
    Abstract
    Cdc7 kinase inhibitors: 2-heteroaryl-3-carboxamido-5-aryl pyrroles as potential anticancer agents
    M. Menichincheri
  • Agosto 22-26
    ACS
    Boston, US
    Web link
    Abstract
    Benzo[d]imidazole/indole inhibitors of coactivator associated argininemethyltransferase 1 (CARM1)
    H. Wan, T. Huynh, S. Pang, J. Geng, T. Bandiera, S. Bindi, P. Vianello, F. Roletto, S. Thieffine, A. Galvani, W. Vaccaro, M. A Poss, G. L Trainor, M. V. Lorenzi, M. Gottardis, L. Jayaraman, A.V. Purandare
  • Luglio 21
    Italian MRI/MRS Users' Meeting
    Torino, IT
    Web link
    Oral presentation
    "In vivo" homing of labelled neural stem cells in a mouse model of spinal cord injury
    A. Degrassi
  • Luglio 8-10
    Secondo Congresso Nazionale di Bioingegneria
    Torino, IT
    Web link
    Abstract 60
    Quantitative evaluation of the Aurora inhibitor effect on gene and protein expression: a mathematical modelling approach
    N. Terranova, R. Bosotti, Carpinelli P, G.Galli, M Bertolotti, P. Magni
  • Giugno, 21-23
    Next generation kinase inhibitors - Oncology and Beyond
    Cambridge, MA
    Web link
    Oral presentation
    Mitotic spindle kinase inhibitors to target aneuploid cancer cells.
    J. Moll

    Oral presentation
    New trends and opportunities in kinase inhibitors design.
    F. Zuccotto
  • Giugno, 8-9
    The 5th annual cell-based assays conference
    Cologne
    Web link
    Oral presentation
    Cell-based profiling and screening assays for protein kinases.
    F. Gasparri
  • Giugno 4-8
    ASCO
    Chicago, US
    Web link
    Abstract 2087
    Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in recurrent malignant glioma (MG).
    A. Benouaich-Amiel, E. Mazza, C. Massard, P. Gaviani, F. Fiorentini, A. Scaburri, M.A. Pacciarini, E. Calvo

    Abstract 3063
    Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors.
    R. Bahleda, A. Spreafico, J. C. Soria, C. Moldovan, C. Belli, F. Fiorentini, A. Scaburri, M.A. Pacciarini, B. L'affranchi, M. Reni

    Abstract 3065
    Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration.
    S. Cresta, C. Sessa, G. Del Conte, A. Locatelli, E. Gallerani, F. Fiorentini, A. Scaburri, M. A. Pacciarini, R. Alzani, L. Gianni

    Abstract 3066
    Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.
    P.J. Rosen, A.W. Tolcher, P. Lee, M. Smitley, M. Fuerst, R. Spinelli, S. Crippa, M.G. Jannuzzo, S. Comis, K. Papadopoulos

    Abstract 5014
    Phase II study of danusertib in advanced/ metastatic breast and ovarian cancers.
    C. Sessa, E. Gallerani, J.P. Delord, P. Schöffski, I. Vergote, V. Trillet-Lenoir, M. Maur, M.G. Jannuzzo, A. Petroccione, G. Locatelli, D. Lorusso
  • Maggio, 26-27
    Targeted Cancer Therapies
    London, EN
    Web link
    Oral presentation
    Cancer Cell Specificity for Cell Cycle Inhibitors - a Paradox or an Opportunity?
    J. Moll
  • Maggio, 16-20
    28th Camerino-Cyprus-Noordwijkerhout Symposium
    Camerino, IT
    Web link
    Oral presentation
    G protein coupled receptors: old landscape with new eyes.
    D. Donati
  • Aprile 17-21
    AACR
    Washington, US
    Web link
    Abstract 691
    In vitro and in vivo characterization of a selective orally available PARP-1 inhibitor with anti-tumor efficacy in BRCA negative cancer models.
    G. Papeo, S. Rainoldi, L.. Gianellini, A. Ciavolella, E. Corti, A. Leone, R. Lupi, F. Sola, F. Caprera, M. Paolucci, R. Perego, C. Albanese, E. Casale, B. Forte, M. Guanci, P. Orsini, H. Posteri, A. Scolaro, F. Riccardi-Sirtori, F. Zuccotto, D. Pezzetta, D. Donati, J. Moll, A. Montagnoli

    Abstract 2522
    Identification and characterization of new highly selective and potent BRAF inhibitors.
    M. Pulici, N. Amboldi, S. Biondaro, F. Caprera, E. Casale, F. Gasparri, A. Leone, R. Lupi, C. Marzoionni, M. Modugno, W. Pastori, G. Traquandi, F. Zuccotto, F. Colotta, D. Donati, E. R. Felder, A. Galvani, A. Isacchi, E. Pesenti, M. Ciomei

    Oral presentation
    NMS-1116354: more than an inhibitor of Cdc7 kinase in S-phase.
    F. Colotta
  • Marzo, 4-6
    TAT
    Bethesda, US
    Web link
    Oral presentation
    Danusertib, a pan-aurora kinase inhibitor: Clinical review.
    B. Laffranchi
  • Febbraio 11-12
    Screening Europe
    Barcelona, SP
    Web link
    Oral presentation
    MPS-1 kinase inhibition in cancer cells: the fast track to cell death.
    J. Moll
  • Febbraio 4-5
    Risonanza Magnetica in Medicina
    Milano, IT
    Web link
    Oral presentation
    MRI and PET evaluation of disease progression and efficacy of a cell cycle inhibitor on a lung adenocarcinoma transgenic mouse model.
    A. Degrassi

Archivio 2009

  • Settembre 13-17
    Eurotox
    Dresdn
    Web link
  • Maggio 29-Giugno 2
    American Society of Clinical Oncology
    Orlando,FL
    Web link
  • Aprile 18-22
    Amercan Association for Cancer Research
    Denver, Co
    Web link
  • Marzo 16-18
    BIO-SPRING
    Milan, Italy
    Web link
  • Marzo 15-19
    SOT
    Baltimore, Maryland
    Web link
  • Marzo 3-4
    8th Annual Protein Kinases Congress 2009
    Barcelona
    Web link
  • Febbraio 23
    Drug Screening 2009
    Berlin, Germany
    Web link
  • Febbraio 23-25
    ADMET
    Berlin,Germany
    Web link
  • Febbraio 13
    Application of Bioanalysis in the Clinical-Pharmaceutical sector
    Catania, Italy
  • Febbraio 8-11
    Chemistry in Cancer Research: A vital parternship in carcer drug discovery and development
    New Orleans
    Web link
  • Gennaio 25
    Keystone Symposium Omics Meet Cell Biology
    Breckenridge, Colorado
    Web link
  • Jannuary 19-22
    Sitox
    Verona
    Web link
  • Gennaio 12
    Model Based Drug Development
    Philadelphia

Archivio 2008

  • Dicembre 6-9
    ASH 50th annual Meeting
    San Francisco
    Web link
  • Dicembre 2nd-3rd
    WDD - 7th World Drug Discovery & Development
    Prague
    Web link
  • Novembre 12-14
    25th LC/MS Montreux Symp of the IAEAC (Int Ass of Environmental Analytical Chem)
    Montreux
    Web link
  • Settembre 30 - Ottobre 2
    CPhI
    Frankfurt
    Web link
  • Ottobre 21-24
    20th EORTC-NCI-AACR Symposium on Molecular Targets& Cancer Therpeutics
    Geneva (Switzerland)
    Web link
  • Ottobre 14-16
    MipTech Conference The Leading European event for Drug Discovery
    Basel
  • Ottobre 5-8
    Eurotox 2008
    Rhodes, Greece
    Web link
  • Settembre 22-25
    SPS, Safety Pharm Society
    Madison, Wisconsin USA
    Web link
  • Settembre 21-26
    ETS: 37th Annual Mtng of the European Teratology Society
    Edinburgh
    Web link
  • Settembre 16-18
    BIOBUSINESS network 2008
    Geneva
  • Settembre 12-16
    ESMO
    Stockholm
    Web link
  • Agosto 31 Settembre 4
    EFMC-ISCM 2008 XXth Int. Symposium on Medicinal Chemistry
    Vienna
    Web link
  • Agosto 17-21
    ACS 236th National Meeting
    Philadelphia
    Web link
  • Giugno 26
    Protein Kinase targets
    Boston
    Web link
  • Giugno 22-25
    2008 AAPS - National Biotechnology Conference
    Toronto
    Web link
  • Giugno 17-20
    BIO - San Diego
    San Diego
    Web link
  • Giugno 12-13
    Isotope Society Meeting
    Bad Soden
    Web link
  • Giugno 8-12
    PBA 2008
    Gdañsk (Polonia)
    Web link
  • Maggio 30- Giugno 3
    ASCO
    Chicago
    Web link
  • Maggio 29 - Giugno 4
    EMBO Meeting - Cellular Signaling & Molecular medicine
    Dubrovnik
    Web link
  • Maggio 19-21
    4th Annual Biomarker World Congress 2008
    Web link
  • Maggio18-21
    10th European ISSX Meeting
    Vienna
    Web link
  • Maggio 18-21
    10th European ISSX Meeting
    Vienna
    Web link
  • Maggio 14-18
    The Cell Cycle
    Cold Spring Harbour (New York)
    Web link
  • Aprile 12-16
    AACR
    San Diego
    Web link
  • Aprile 7-9
    Bio Europe Spring 2008
    Madrid
    Web link
  • Agosto 17-21
    ACS 235th National Meeting
    New Orleans
    Web link
  • Aprile 6 -10
    SBS Meeting
    Web link
  • Marzo 16-20
    SOT
    Seattle
    Web link
  • Marzo 10-11
    Development of safe protein Therapeutics: preclinical, clinical and regulatory issues - EUFEPS
    Munich
    Web link
 
Per offrirti un'esperienza di navigazione ottimizzata NMS Group e le società controllate utilizzano cookies, anche di terze parti.
Proseguendo con la navigazione acconsenti al loro impiego in conformità della nostra  
Cookie Policy.